Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Proteome Sciences plc    PRM   GB0003104196

PROTEOME SCIENCES PLC (PRM)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
04/17/2018 04/18/2018 04/19/2018 04/20/2018 04/23/2018 Date
3.41(c) 3.51(c) 3.76(c) 3.71(c) 3.76(c) Last
125 000 1 258 462 377 791 932 320 000 Volume
-2.85% +2.93% +7.12% -1.33% +1.35% Change
More quotes
Financials (GBP)
Sales 2017 4,10 M
EBIT 2017 -1,60 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
Sales 2018 -
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 -
Capi. / Sales2017 2,69x
Capi. / Sales2018 -
Capitalization 11,0 M
More Financials
Company
Proteome Sciences Plc is engaged in applied proteomics and peptidomics services and applications.It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development.The company focuses on developing proprietary protein biomarkers for neurological... 
More about the company
Latest news on PROTEOME SCIENCES PLC
04/04PROTEOME SCIENCES : Subsidiary Amends Deal With Pierce Biotechnology
AQ
04/04PROTEOME SCIENCES : amends distribution pact with Pierce Biotechnology
AQ
03/01PROTEOME SCIENCES : Data on Alzheimer Disease Reported by Researchers at Proteom..
AQ
2017PROTEOME SCIENCES : announce Good Clinical Laboratory Practice accreditation
AQ
2017PROTEOME SCIENCES : Interim results for the six months ended 30 June 2017
PU
2017PROTEOME SCIENCES : Stroke Diagnostic Presentation at EuroMedLab 2017 – Re..
PU
2017THERMO FISHER SCIENTIFIC : Recognizes Tandem Mass Tag Grant Award Winners at ASM..
AQ
2017PROTEOME SCIENCES : AGM Statement and Result of AGM
PU
2017PROTEOME SCIENCES : Trading Remains In Line With Expectations
AQ
2017PROTEOME SCIENCES : Appointment of Richard Dennis as Chief Commercial Officer
PU
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/12Proteome Sciences's corporate rating reiterated at FinnCap. GBX 7 PT.  
2017Proteome Sciences plc's corporate rating reiterated at FinnCap.  
2017$PRM - Martin Diggle Purchases 119,636 Shares of Proteome Sciences plc #PRM S.. 
2017Proteome Sciences plc's corporate rating reiterated at FinnCap.  
2017Proteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
More tweets
Qtime:43
Chart PROTEOME SCIENCES PLC
Duration : Period :
Proteome Sciences plc Technical Analysis Chart | PRM | GB0003104196 | 4-Traders
Technical analysis trends PROTEOME SCIENCES PLC
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Jeremy Rupert Michael Haigh Chief Executive Officer & Executive Director
Christopher D. J. Pearce Non-Executive Chairman
Stefan Fuhrmann Finance Director
Ian H. Pike Executive Director & Chief Scientific Officer
Roger Steven McDowell Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOME SCIENCES PLC20.32%15
GILEAD SCIENCES3.31%96 094
VERTEX PHARMACEUTICALS5.89%40 153
REGENERON PHARMACEUTICALS-15.95%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998